Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

NICE Issues Technical Guidance on Otovent Balloon that Could Reduce Childhood Surgery and Save the NHS Millions


News provided by

Kestrel Medical Ltd

14 Mar, 2016, 18:09 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Otovent(R) Glue Ear Treatment ( www.gluear.co.uk ) (PRNewsFoto/Kestrel Medical) (PRNewsFoto/Kestrel Medical)
This image opens in the lightbox
Otovent(R) is suitable for adults and children from 3 years of age (PRNewsFoto/Kestrel Medical) (PRNewsFoto/Kestrel Medical)
This image opens in the lightbox
Paediatrician Dr Ranj Singh says that "parents have a relatively non-invasive and low-cost option for helping to treat their child's glue ear before thinking about surgery (PRNewsFoto/Kestrel Medical Ltd) (PRNewsFoto/Kestrel Medical Ltd)

BROADSTONE, England, March 14, 2016 /PRNewswire/ --

An auto inflation device could be used as a first-line non-surgical, drug-free treatment option for glue ear according to a new report published by the National Institute for Health and Care Excellence.

     (Logo: http://photos.prnewswire.com/prnh/20160314/343863LOGO )

     (Photo: http://photos.prnewswire.com/prnh/20160314/343864 )

     (Photo: http://photos.prnewswire.com/prnh/20160314/343873 )
Otovent, from Kestrel Medical, offers a non-invasive alternative to antibiotics and surgery for the 80% of children in the UK that suffer with Otitis Media with Effusion[1] and should be used as a first-line treatment during or after the period of active observation following diagnosis, according to the report. Otovent works by using pressure from a balloon to help drain fluid that gets trapped in the middle ear and causes subsequent hearing problems.

As pointed out by the specialist commentators, parents are often disheartened when told to wait for three months to see if the symptoms of glue ear improve. They are therefore keen to try this treatment as it may reduce the need for grommet surgery and does not require high level monitoring as opposed to hearing aids. Otovent will also allow parents to initially treat children in the home environment, without having to rely on antibiotics or surgery.

According to the report, Otovent can easily be incorporated into NHS clinics, along with information on the effectiveness and instruction on the method. If no clinician is available to show how to use the device correctly, there are a number of instructional videos available on the internet.

The report reviews four randomised clinical trials on Otovent involving a total of 565 children. All trials showed statistically significant improvements in middle ear function with Otovent compared with standard care. The improvements were determined by pneumatic optometry and tympanometry. No serious adverse effects associated with using the Otovent balloon were reported.

The latest trial of 320 children aged 4 to 11 years, undertaken by Dr Williamson at the University of Southampton, found that children using Otovent experienced fewer days with any glue-ear related symptoms compared to those that didn't at both one (47.3% and 35.6%, respectively) and three months (49.6% and 38.3%, respectively). Otovent also produced greater improvements in ear-related quality of life assessed using the validated tool, a 14-point questionnaire on the impact of OME (OMQ-14).

Paediatrician Dr Ranj Singh said: 'Glue ear can be problematic and frustrating for children and their parents.  Despite the potentially significant consequences on development, there has traditionally been little in the way of treatment, other than surgery.  Now for the first time, there is a real alternative that has clinically-proven results.

'By using an auto-inflation device, parents have a relatively non-invasive and low-cost option for helping to treat their child's glue ear before thinking about surgery, potentially avoiding antibiotics.  Such an easy-to-use and effective treatment has been long overdue!

It goes on to suggest that this treatment should be used more widely in children over the age of four to manage Otitis Media with Effusion and help treat the associated hearing loss.

Otovent consists of a small nasal device attached to a balloon which the child inflates through their nose. The act of blowing up the balloon helps to open up the Eustachian tube, making it easier for the fluid to drain from the middle ear and if used properly, the child's hearing can improve in just a few days.

Otitis Media with Effusion, commonly known as Glue Ear, is a widespread condition that affects around 200,000 children every year in the UK and is most common in children under the age of ten[2]. It's caused when a sticky, glue-like fluid fills the middle ear and causes the child to have problems hearing. Ongoing hearing loss or pain often results in a grommet operation, which is the most common reason for general anaesthetic in children.

About Otovent  

Otovent is a proven effective form of treatment for reducing the symptoms of glue ear (Otitis Media with Effusion). It is the only clinically effective, non-surgical and drug free treatment for glue ear.

Link to the report (published on 15th March 2015): https://www.nice.org.uk/advice/mib59

Otovent is a small balloon which the child inflates through their nose. The act of blowing up the balloon helps to open up the Eustachian tube, making it easier for fluid to drain from the middle ear. The Otovent balloon equalises the pressure to relieve the symptoms in the middle ear.

Otovent needs to be used three times a day until all the fluid has drained away. Results can often be seen as early as a few days into using it.

The Otovent method is a clinically proven first-line treatment option to help avoid the surgical insertion of tubes into the eardrum. It is a non-surgical, drug free treatment for glue ear, and has been recommended by ENT specialists for the last 20 years. The child inflates a small balloon using their nose, and at the same time equalises the pressure and relieves the symptoms in the middle ear. Blowing up the balloon helps to open up the Eustachian tube, making it easier for fluid to drain from the middle ear. Otovent should be used 2-3 times daily until all the fluid has been drained a day.

Who can use Otovent 

Adults and children from 3 years of age can be treated with Otovent. Children can use Otovent at home under parental supervision. It is painless, harmless and takes only a matter of seconds to perform.

Each pack of Otovent contains 

  • 1 x Nosepiece
  • 5 x Balloons
  • 1 x Carry Case

How to use Otovent 

  1. Connect the balloon to the nose piece. Hold the round part of the nose piece firmly against the right nostril with the right hand. Press the left nostril closed with the left hand.
  2. Inhale deeply, close the mouth and inflate the balloon until it is the size of a grapefruit, by blowing through the nostril.
  3. Repeat the procedure with the left nostril.

Where to buy Otovent  

Otovent is available on prescription, Boots stores, pharmacies and online from http://www.gluear.co.uk.

[1] http://www.nhs.uk  

[2] Zeilhuis

Press enquiries: George Ponsford +44-(0)1202)-658-444
Email:George@kestrelmedical.co.uk / luke@kestrelmedical.co.uk    
Issued by: Kestrel Medical Ltd  

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.